Nelson Vergel
Founder, ExcelMale.com
By Nelson Vergel | Updated April 24, 2026 | 7 min read
If you've been using compounded peptides — or considering them — the FDA just made several moves that directly affect what's available and what's coming under review. The agency updated its official 503A bulk drug substances list on April 15, 2026, and the changes impact some of the most widely discussed peptides in the longevity and men's health community, including BPC-157, TB-500, Semax, Epitalon, and Melanotan II.
Here's what the update actually says, what it means for access, and what to watch for in the coming months.
What Is the FDA's 503A List — and Why Does It Matter for Peptides?
Compounding pharmacies that make custom formulations — including hormone therapies, peptides, and nutrients — operate under Section 503A of the Federal Food, Drug, and Cosmetic Act. The FDA maintains a running list of bulk drug substances divided into three categories:
• Category 1 — Under Evaluation: The FDA is actively reviewing the evidence. Compounding is generally permitted while the review is in progress.
• Category 2 — Significant Safety Concerns: The FDA has flagged these substances. Compounding is restricted or strongly discouraged.
• Category 3 — Nominated Without Adequate Support: Not enough scientific backing was submitted. These substances are essentially on hold with no active review.
Where a substance lands on this list determines whether a licensed compounding pharmacy can legally make it and whether a prescriber can order it for a patient.
What Changed in the April 2026 Update?
Several Major Peptides Are Being Removed from Category 2
This is the most significant headline: the FDA is removing more than a dozen peptides from Category 2 — the "safety concerns" list. However, this is not a green light to compound freely. The nominations were withdrawn by industry nominators, and the FDA is now scheduling formal advisory committee reviews before making final decisions.
Here is the full list of peptides being removed from Category 2, along with their scheduled review dates:
The advisory committee involved is the Pharmacy Compounding Advisory Committee (PCAC). Their meetings are public, and their recommendations carry real weight with the FDA's final decisions.
GHK-Cu Topicals Stay in Category 1
GHK-Cu (copper peptide) is split across categories. The non-injectable form — meaning topical applications — remains in Category 1 under active evaluation, so compounded topical GHK-Cu is still available through licensed pharmacies. Only injectable GHK-Cu falls into the review process above.
What's Still Available Through Compounding Pharmacies?
Category 1 contains a large number of substances the FDA is still evaluating favorably. Many are directly relevant to men's health and hormone optimization. Key ones currently in Category 1 include:
• NAD+ / NADH — widely used for energy metabolism and longevity support
• Glutathione — antioxidant commonly given IV or via injection
• Enclomiphene Citrate — an alternative to clomiphene for stimulating natural testosterone production without estrogenic side effects
• Pregnenolone — precursor hormone used in hormone optimization protocols
• Melatonin — compounded forms at custom doses
• L-Citrulline — used for nitric oxide support and cardiovascular health
• Vasoactive Intestinal Peptide (VIP) — used in some mast cell and long COVID protocols
• Alpha Lipoic Acid, CoQ10, Resveratrol, Quercetin — common antioxidant compounds
• GHK-Cu (non-injectable) — topical copper peptide for skin and tissue repair
What Does This Mean Practically for Men Using Peptides?
BPC-157 and TB-500 Are Not Banned
Both remain in a regulatory gray zone — not approved, not explicitly banned, but now headed toward a formal advisory committee review. Some compounding pharmacies may become more cautious in the months leading up to the July 2026 PCAC meetings, even without an explicit restriction.
If you're currently using BPC-157 or TB-500 through a licensed compounding pharmacy with a valid prescription, your best move is to stay in contact with your pharmacy and prescribing physician about any changes.
July 2026 Is the Critical Window
The PCAC meetings on July 23-24, 2026 will be public hearings where scientific evidence, safety data, and clinical use cases for these peptides will be presented and debated. The committee's recommendations will heavily shape whether BPC-157, TB-500, Semax, KPV, MOTs-C, and Epitalon end up on the approved compounding list or face restrictions.
Access May Tighten Before It Improves
In regulatory cycles like this one, the period between withdrawal of nominations and a final advisory committee ruling is often when access gets most uncertain. Pharmacies navigating legal risk may slow production of affected peptides even if no explicit ban is in place.
The Substances Are Not Being "Forgotten"
The FDA explicitly stated its intent to consult the PCAC on each of these substances — that means the review process is actually moving forward in a more structured way than before. For advocates and the compounding industry, that's a better outcome than being left in indefinite Category 2 limbo.
What Is the PCAC and How Can You Follow the Hearings?
The Pharmacy Compounding Advisory Committee advises the FDA on the safety and appropriateness of substances used in compounding. Meetings are public, and FDA often accepts written public comments in advance.
Frequently Asked Questions
Is BPC-157 still legal to use in 2026?
BPC-157 is not an FDA-approved drug. It exists in a compounding gray zone — it has been on the Category 2 safety concern list, is now being moved out of that category, and a formal FDA advisory committee review is scheduled for July 23, 2026. Personal use of compounded BPC-157 obtained with a valid prescription from a licensed pharmacy has not been explicitly criminalized, but the regulatory landscape is changing. Always consult your prescribing physician.
What is TB-500 and will I still be able to get it?
TB-500 is the popular name for Thymosin Beta-4 Fragment (LKKTETQ), a synthetic peptide used by many men for injury recovery, inflammation reduction, and tissue repair. It was on the FDA's Category 2 list and is being moved to formal PCAC review in July 2026. Access through compounding pharmacies may become more uncertain in the lead-up to that meeting.
Are any peptides definitively approved for compounding?
Peptides in Category 1 are under active evaluation and generally available through licensed 503A compounding pharmacies with a valid prescription. However, "under evaluation" is not the same as "FDA-approved." No compounded bulk peptide has full FDA drug approval. Category 1 status simply means the review process is ongoing and compounding is not currently restricted.
Does this affect peptides I buy online without a prescription?
Yes — and significantly. Research chemical or "not for human consumption" peptide sources operate entirely outside the FDA's compounding framework. This update doesn't change their legal status, which was already non-compliant. The FDA's actions focus on licensed 503A compounding pharmacies and what they can legally produce for patients.
What should I do if my compounding pharmacy stops making my peptide?
Talk to your prescribing physician first. Depending on the peptide, there may be alternative compounded options in Category 1, or your doctor may recommend adjusting your protocol based on what's available. Do not source peptides from unregulated online vendors as a substitute.
Conclusion
The FDA's April 2026 update doesn't end access to popular peptides overnight, but it does move the regulatory clock forward on a formal reckoning. The July 23-24, 2026 PCAC meetings are the most important near-term dates to watch — they will shape the future of BPC-157, TB-500, Semax, MOTs-C, KPV, Epitalon, and several other compounds that many men in our community use for recovery, longevity, and performance.
Stay informed, keep the lines open with your prescribing physician, and follow the public PCAC process. The advocacy community has real input opportunities here — and the more well-documented clinical use cases the FDA sees, the better the evidence record becomes.
Related Reading on ExcelMale
Peptide Therapy and Clinical Dosages: What Men on TRT Need to Know
BPC-157 Dosage: Maximize Benefits with Proper Use
TB-500 Peptide: The Future of Regenerative Medicine
Enclomiphene vs TRT: Where Does It Really Fit in Today's HRT Landscape?
NAD+: Hype or Miracle Molecule? (Includes IV Infusion Experience)
How to Find a TRT Doctor Near You (2026 Guide): Online & Local Options
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or modifying any hormone therapy, peptide protocol, or medical treatment.
Source: FDA 503A Bulk Drug Substances List, updated April 15, 2026 fda.gov/media/94155/download
If you've been using compounded peptides — or considering them — the FDA just made several moves that directly affect what's available and what's coming under review. The agency updated its official 503A bulk drug substances list on April 15, 2026, and the changes impact some of the most widely discussed peptides in the longevity and men's health community, including BPC-157, TB-500, Semax, Epitalon, and Melanotan II.
Here's what the update actually says, what it means for access, and what to watch for in the coming months.
| In this article you will learn: what the FDA's 503A list is and why it matters, which peptides are being removed from the safety-concern list, what's still available through compounding pharmacies, and what the July 2026 advisory committee hearings could mean for long-term access. |
What Is the FDA's 503A List — and Why Does It Matter for Peptides?
Compounding pharmacies that make custom formulations — including hormone therapies, peptides, and nutrients — operate under Section 503A of the Federal Food, Drug, and Cosmetic Act. The FDA maintains a running list of bulk drug substances divided into three categories:
• Category 1 — Under Evaluation: The FDA is actively reviewing the evidence. Compounding is generally permitted while the review is in progress.
• Category 2 — Significant Safety Concerns: The FDA has flagged these substances. Compounding is restricted or strongly discouraged.
• Category 3 — Nominated Without Adequate Support: Not enough scientific backing was submitted. These substances are essentially on hold with no active review.
Where a substance lands on this list determines whether a licensed compounding pharmacy can legally make it and whether a prescriber can order it for a patient.
What Changed in the April 2026 Update?
Several Major Peptides Are Being Removed from Category 2
This is the most significant headline: the FDA is removing more than a dozen peptides from Category 2 — the "safety concerns" list. However, this is not a green light to compound freely. The nominations were withdrawn by industry nominators, and the FDA is now scheduling formal advisory committee reviews before making final decisions.
Here is the full list of peptides being removed from Category 2, along with their scheduled review dates:
| Peptide | PCAC Review Date |
| BPC-157 | July 23, 2026 |
| TB-500 (Thymosin Beta-4 Fragment) | July 23, 2026 |
| MOTs-C | July 23, 2026 |
| KPV | July 23, 2026 |
| Semax | July 24, 2026 |
| Epitalon | July 24, 2026 |
| Emideltide (DSIP) | July 24, 2026 |
| Melanotan II | By February 2027 |
| GHK-Cu (injectable only) | By February 2027 |
| Dihexa Acetate | By February 2027 |
| PEG-MGF | By February 2027 |
| Cathelicidin LL-37 | By February 2027 |
The advisory committee involved is the Pharmacy Compounding Advisory Committee (PCAC). Their meetings are public, and their recommendations carry real weight with the FDA's final decisions.
GHK-Cu Topicals Stay in Category 1
GHK-Cu (copper peptide) is split across categories. The non-injectable form — meaning topical applications — remains in Category 1 under active evaluation, so compounded topical GHK-Cu is still available through licensed pharmacies. Only injectable GHK-Cu falls into the review process above.
What's Still Available Through Compounding Pharmacies?
Category 1 contains a large number of substances the FDA is still evaluating favorably. Many are directly relevant to men's health and hormone optimization. Key ones currently in Category 1 include:
• NAD+ / NADH — widely used for energy metabolism and longevity support
• Glutathione — antioxidant commonly given IV or via injection
• Enclomiphene Citrate — an alternative to clomiphene for stimulating natural testosterone production without estrogenic side effects
• Pregnenolone — precursor hormone used in hormone optimization protocols
• Melatonin — compounded forms at custom doses
• L-Citrulline — used for nitric oxide support and cardiovascular health
• Vasoactive Intestinal Peptide (VIP) — used in some mast cell and long COVID protocols
• Alpha Lipoic Acid, CoQ10, Resveratrol, Quercetin — common antioxidant compounds
• GHK-Cu (non-injectable) — topical copper peptide for skin and tissue repair
What Does This Mean Practically for Men Using Peptides?
BPC-157 and TB-500 Are Not Banned
Both remain in a regulatory gray zone — not approved, not explicitly banned, but now headed toward a formal advisory committee review. Some compounding pharmacies may become more cautious in the months leading up to the July 2026 PCAC meetings, even without an explicit restriction.
If you're currently using BPC-157 or TB-500 through a licensed compounding pharmacy with a valid prescription, your best move is to stay in contact with your pharmacy and prescribing physician about any changes.
July 2026 Is the Critical Window
The PCAC meetings on July 23-24, 2026 will be public hearings where scientific evidence, safety data, and clinical use cases for these peptides will be presented and debated. The committee's recommendations will heavily shape whether BPC-157, TB-500, Semax, KPV, MOTs-C, and Epitalon end up on the approved compounding list or face restrictions.
Access May Tighten Before It Improves
In regulatory cycles like this one, the period between withdrawal of nominations and a final advisory committee ruling is often when access gets most uncertain. Pharmacies navigating legal risk may slow production of affected peptides even if no explicit ban is in place.
The Substances Are Not Being "Forgotten"
The FDA explicitly stated its intent to consult the PCAC on each of these substances — that means the review process is actually moving forward in a more structured way than before. For advocates and the compounding industry, that's a better outcome than being left in indefinite Category 2 limbo.
What Is the PCAC and How Can You Follow the Hearings?
The Pharmacy Compounding Advisory Committee advises the FDA on the safety and appropriateness of substances used in compounding. Meetings are public, and FDA often accepts written public comments in advance.
| If you want to advocate for continued access to any of these peptides, submitting public comments — especially clinical use case documentation or published research references — is one concrete way to participate in the process. Monitor the FDA advisory committee calendar at fda.gov/advisory-committees for meeting announcements and docket numbers. |
Frequently Asked Questions
Is BPC-157 still legal to use in 2026?
BPC-157 is not an FDA-approved drug. It exists in a compounding gray zone — it has been on the Category 2 safety concern list, is now being moved out of that category, and a formal FDA advisory committee review is scheduled for July 23, 2026. Personal use of compounded BPC-157 obtained with a valid prescription from a licensed pharmacy has not been explicitly criminalized, but the regulatory landscape is changing. Always consult your prescribing physician.
What is TB-500 and will I still be able to get it?
TB-500 is the popular name for Thymosin Beta-4 Fragment (LKKTETQ), a synthetic peptide used by many men for injury recovery, inflammation reduction, and tissue repair. It was on the FDA's Category 2 list and is being moved to formal PCAC review in July 2026. Access through compounding pharmacies may become more uncertain in the lead-up to that meeting.
Are any peptides definitively approved for compounding?
Peptides in Category 1 are under active evaluation and generally available through licensed 503A compounding pharmacies with a valid prescription. However, "under evaluation" is not the same as "FDA-approved." No compounded bulk peptide has full FDA drug approval. Category 1 status simply means the review process is ongoing and compounding is not currently restricted.
Does this affect peptides I buy online without a prescription?
Yes — and significantly. Research chemical or "not for human consumption" peptide sources operate entirely outside the FDA's compounding framework. This update doesn't change their legal status, which was already non-compliant. The FDA's actions focus on licensed 503A compounding pharmacies and what they can legally produce for patients.
What should I do if my compounding pharmacy stops making my peptide?
Talk to your prescribing physician first. Depending on the peptide, there may be alternative compounded options in Category 1, or your doctor may recommend adjusting your protocol based on what's available. Do not source peptides from unregulated online vendors as a substitute.
Conclusion
The FDA's April 2026 update doesn't end access to popular peptides overnight, but it does move the regulatory clock forward on a formal reckoning. The July 23-24, 2026 PCAC meetings are the most important near-term dates to watch — they will shape the future of BPC-157, TB-500, Semax, MOTs-C, KPV, Epitalon, and several other compounds that many men in our community use for recovery, longevity, and performance.
Stay informed, keep the lines open with your prescribing physician, and follow the public PCAC process. The advocacy community has real input opportunities here — and the more well-documented clinical use cases the FDA sees, the better the evidence record becomes.
Related Reading on ExcelMale
Peptide Therapy and Clinical Dosages: What Men on TRT Need to Know
BPC-157 Dosage: Maximize Benefits with Proper Use
TB-500 Peptide: The Future of Regenerative Medicine
Enclomiphene vs TRT: Where Does It Really Fit in Today's HRT Landscape?
NAD+: Hype or Miracle Molecule? (Includes IV Infusion Experience)
How to Find a TRT Doctor Near You (2026 Guide): Online & Local Options
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or modifying any hormone therapy, peptide protocol, or medical treatment.
Source: FDA 503A Bulk Drug Substances List, updated April 15, 2026 fda.gov/media/94155/download
